ArtiMed is developing AI-based risk stratification software-as-a-service (SaaS) tools. These tools are designed to assist health plans and insurers to manage the challenges presented by long Covid and other post-Covid conditions within their populations. Additionally, they enable pharmaceutical companies in identifying individuals who might benefit from their drugs for these conditions. ArtiMed has recently expanded its portfolio to broadened its scope to include risk stratification for other post-Covid issues such as major cardiovascular conditions, including myocardial infarction or stroke, associated with a previous Covid infection.